NOMAD Power Solutions, Inc. (NMAD) is a Nasdaq-listed micro-cap that builds truck-transportable, utility-grade battery energy storage systems — branded Traveler, Voyager Eagle, Voyager Falcon and Voyager Hawk — for utilities, data centers, industrial operators and critical infrastructure. The company, formerly Lixte Biotechnology, pivoted into AI energy infrastructure following its merger with NOMAD Transportable Power Systems.
Shares closed Wednesday at $2.73, down $0.27, or 9.00%, from the prior close of $3.00. The direction was unmistakably lower: the stock gave back a large part of the two-session rebound that had lifted it 19.1% and 7.1% on Monday and Tuesday. The immediate reason cited by the market is the contents of the third-quarter filing published after Monday's close, which showed shrinking revenue against a widening per-share loss, combined with continuing uncertainty over leadership and funding.
The 10-Q for the quarter ended September 30, released after Monday's closing bell, was the first quarterly report since the July 1 merger with NOMAD Transportable Power Systems closed. It delivered a genuinely mixed set of numbers.
On the positive side, backlog exceeded $30 million, supported by roughly $14 million in non-refundable customer deposits. Deferred revenue rose to $9.6 million from $8.2 million at year-end, a gain of 18%, and the utility sales organization expanded to 26 states with 43 representatives.
Against that, sales came in at $472,000 versus $652,000 a year earlier, and the quarterly loss reached $0.74 per share. Cash stood at roughly $12.7 million. For a company guiding toward a production ramp in the first quarter of 2027, the gap between a $30 million order book and sub-$1 million of quarterly revenue puts the funding burden squarely in focus. Investors sold first and asked questions later.
Geordan Pursglove stepped down as chairman, CEO and director effective November 6, with Michael Hilmer — an entrepreneur and capital markets executive — taking over as chairman and interim CEO. Filings disclosed a $600,000 severance payment and 1.5 million restricted stock units granted to Pursglove as a consultant, equal to roughly 9% of the 16.1 million shares outstanding.
For a stock with a market capitalization near $44 million, an equity award of that size, layered on top of an interim chief executive and an unresolved history of Nasdaq listing-agreement matters, reinforces a dilution and execution discount that has kept sellers active on rallies.
The decline is best read as the unwinding of an oversold bounce rather than a fresh shock. Shares had collapsed 36.5% on November 13 to $2.35 — the sharpest single-session drop in the recent record — before rebounding to $2.80 and then $3.00. That recovery stalled at the round-number $3 level, and Wednesday's session handed those gains back.
The selling was concentrated in this name rather than reflecting a macro or sector-wide shock. Volume has been the tell: Tuesday's 525,260 shares traded was more than double the 20-day average of roughly 222,000, and Wednesday's early tape showed thin, uneven liquidity typical of a stock with a small float and light institutional ownership. Short interest sits near 960,000 shares, or about 6% of shares outstanding, with roughly 4.6 days to cover.
Technically, the shares trade below both the 50-day average near $3.76 and the 200-day average near $4.26, with the 52-week range stretching from $2.31 to $8.38. The November low of $2.31 is the obvious support level in focus; a failure there would put the stock at a new annual low.
The score runs from 0 — no meaningful news and a move that is normal for the stock — to 100, meaning transformative news and an extreme, rare price move. This event scores 28 out of 100.
The verified news was moderate rather than transformative: a quarterly filing with weaker revenue and a larger per-share loss, offset by a growing backlog, and a leadership transition that was already announced. Judged against a roughly $44 million market cap, the disclosure is material but not decisive. The price move was roughly twice the stock's average absolute daily change of about 4.5%, and six sessions in the past 70 produced equal or larger moves, which caps the anomaly contribution. Moderate news and a moderately unusual move combine into a mid-20s score.
The fourth quarter of 2026 will be the first full period under the new leadership team, and management has signaled that deliveries and revenue recognition should accelerate alongside the planned first-quarter 2027 production ramp. Investors will want evidence that the $30 million backlog converts into shipped systems rather than remaining on the order book.
Cash runway is the central risk. With quarterly losses of this magnitude and capital spending ahead, another equity raise or debt facility is plausible, and the terms will matter enormously for a float this small. Additional variables include resolution of Nasdaq listing requirements, certification and utility contract milestones, and the disposal of the legacy life sciences assets. There is no formal sell-side coverage or consensus target on file, so price discovery will remain driven by filings, press releases and order announcements.
Tickeron maintains hundreds of AI trading bots spanning thousands of tickers, but only the strongest performers under current market conditions are surfaced in its curated Trending AI Robots section. The bots differ widely by strategy, timeframe, performance metrics and traded symbols, so the list offers a useful cross-section of what is actually working in live conditions rather than a single one-size-fits-all approach. Explore the page to see how systematic strategies are positioned right now.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry ElectricalProducts